Research performed during the last several years implicates important roles for a variety of growth factors that affect osteoblasts or their precursors during bone development, remodeling, or repair. Of these, three families of growth factors in particular-the transforming growth factor betas (TGF-βs), insulin-like growth factors (IGFs), and bone morphogenetic proteins (BMPs)-are considered to be principal local regulators of osteogenesis, although none is specific for cells of the osteoblast lineage. Therefore, mechanisms to induce skeletal tissue specificity might occur through interactions among these growth factors, with circulating hormones, or through specific intracellular mediators. In the latter case, even more recent studies point to two nuclear transcription factors, termed Core Binding Factor al (CBFal) and CCAAT/Enhancer Binding Protein 8 (C/EBP8), as significant regulators of the expression or activity of specific bone growth factors or their receptors. Perhaps more importantly, events that link these growth factors to nuclear proteins occur in response to glucocorticoids, sex steroids, parathyroid hormone (PTH), or prostaglandin E2 (PGE2), which themselves have well-known effects on bone biology. in this review, we discuss the situations and processes that initially suggested growth-factor- and hormone-specific interactions on cells within the osteoblast lineage, and present evidence for roles that CBFa I and C/EBP8 have on osteoblast function. Finally, we offer examples for how these factors integrate events that are associated with various aspects of bone formation.
References
1.
Atchley WR, Hall BK ( 1991). A model for development and evolution of complex morphological structures, Biol Rev Camb Philos Soc66:101-157.
2.
Aubin JE (1999). Osteoprogenitor cell frequency in rat bone marrow stromal populations: role for heterotypic cell-cell interactions in osteoblast differentiation, J Cell Biochem72:396-410.
3.
Bae S.-C., Ogawa E., Maruyama M., Oka H., Satake M., Shigesada K., et al. (1994). PEBP2alphaB/mouse AMLI consists of multiple isoforms that possess differential transactivation potentials, Mol Cell Biol14:3242-3252,
4.
Banerjee C., Hiebert SW, Stein JL, Lian JB, Stein GS (1996). An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc Natl Acad Sci USA93:4968-4973.
5.
Baneriee C., McCabe LR, Choi J.-Y., Hiebert SW, Stein JL, Stein GS, et al. (1997). Runt homology domain proteins in osteoblast differentiation: AML3/CBFa1 is a major component of a bone-specific complex. ) J Cell Biochem66:1-8.
6.
Barrett TJ, Spelsberg TC (1998). Steroid receptors at the nexus of transcriptional regulation. J Cell Biochem3031(Suppl):185-193.
7.
Boonen S., Broos P., Dequeker J., Bouillon R. (1997). The prevention or treatment of age-related osteoporosis in the elderly by systemic recombinant growth factor therapy (rhlGF-I or rhTGF beta): a perspective. J Intern Med242:285-290.
8.
Bostrom MP (1998). Expression of bone morphogenetic proteins in fracture healing. Clin Orthop355(Suppl):S116-S123.
9.
Britos-Bray M., Friedman AD (1997). Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol17:5127-5135.
10.
Bryant HU, Glasebrook AL, Yang NN, Sato M. ( 1999). An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol69:37-44.
11.
Burke D., Wilkes D., Blundell TL, Malcolm S. (1998). Fibroblast growth factor receptors: lessons from the genes. Trends Biochem Sci23:59-62.
12.
Canalis E., Varghese S., McCarthy TL, Centrella M. (1992). Role of platelet derived growth factor in bone cell function. Growth Regul2:151-155.
13.
Cantwell CA, Sterneck E., Johnson PF (1998). Interleukin-6-specific activation of the C/EBP 8 gene in hepatocytes is mediated by Stat3 and Spl. Mol Cell Biol18:2108-2117.
14.
Centrella M., Canalis E. (1985). Transforming and non-transforming growth factors are present in culture medium conditioned by fetal rat calvariae. Proc Natl Acad Sci USA82:7335-7339.
15.
Centrella M., Massague J., Canalis E. (1986). Human platelet-derived transforming growth factor beta stimulates parameters of bone growth in fetal rat calvariae. Endocrinology119:2306-2312.
16.
Centrella M., McCarthy TL, Canalis E. (1987). Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat calvariae. J Biol Chem262:2869-2874.
17.
Centrella M., McCarthy TL, Canalis E. (1991). Glucocorticoid regulation of transforming growth factor β1 (TGF-β1) activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol11:4490-4496.
18.
Centrella M., McCarthy TL, Canalis E. (1992a). Growth factors and cytokines. In: Bone. Vol.4. Bone metabolism and mineralization. Hall BK, editor. Boca Raton, FL: CRC Press Inc., pp. 47-72.
19.
Centrella M., McCarthy TL, Kusmik WF, Canalis E. (1992b). Isoform specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. J Clin Invest89:1076-1084.
20.
Centrella M., Rosen V., Horowitz MC, Wozney JM, McCarthy TL (1995a). Transforming growth factor-β gene family members, their receptors, and bone cell function. In: Hormonal regulation of bone mineral metabolism. Bikle DD, Negro-Vilar A, editors. Bethesda, MD: Endocrine Society Press, pp. 211-226.
21.
Centrella M., Kim J., Pham T., Casinghino S., Rosen V., Wozney J., et al. (1995b). Independent changes in type I and type II receptors for transforming growth factor β induced by bone morphogenetic protein-2 parallel expression of the osteoblast phenotype. Mol Cell Biol15:3273-3281.
22.
Chambers TJ, Chow JW, Fox SW, Jagger C.), Lean JM ( 1997). The role of prostaglandins and nitric oxide in the response of bone to mechanical stimulation. Adv Exp Med Biol433:295-298.
23.
Chang D.), Ji C., Kim KK, Casinghino S., McCarthy TL, Centrella M. (1998). Reduction in transforming growth factor β receptor I and transcription factor CBFal on bone cells by glucocorticoid. I Biol Chem273:4892-4896.
24.
Chow JW, Fox SW, Lean JM, Chambers TJ (1998). Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res13:1039-1044.
25.
Corsello SM, Rota CA, Putignano P., Della Casa S., Barnabei A., Migneco MG, et al. (1998). Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. Eur J Endocrinol39:309-313.
26.
Cosman F., Lindsay R. (1998). Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int62:475-480.
27.
Cozzi R., Attanasio R., Oppozzi G., Orlandi P., Giustina A., Lodrini S., et al. (1997). Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest20:445-451.
28.
Croniger C., Leahy P., Reshef L., Hanson RW (1998). C/EBP and the control of phosphoenolpyruvate carboxykinase gene transcription in the liver. J Biol Chem273:31629-31632.
29.
Darlington GJ, Ross SE, MacDougald OA (1998). The role of C/EBP genes in adipocyte differentiation. J Biol Chem273:30057-30060.
30.
Descombes P., Chojkier M., Lichsteiner S., Falvey E., Schibler U. (1990). LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcription activator protein. Genes Dev4:1541-1551.
31.
Diehl AM (1998). Roles of CCAAT/enhancer-binding proteins in regulation of liver regenerative growth. J Biol Chem273:30843-30846.
32.
Ducy P., Zhang R., Geoffrey V., Ridall AL, Karsenty G. (1997). Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell89:747-754.
33.
Duneas N., Crooks J., Ripamonti U. (1998). Transforming growth factor-beta 1: induction of bone morphogenetic protein genes expression during endochondral bone formation in the baboon, and synergistic interaction with osteogenic protein-1 (BMP-7). Growth Factors15:259-277.
34.
Dunn NR, Winnier GE, Hargett LK, Schrick JJ, Fogo AB, Hogan BL (1997). Haploinsufficient phenotypes in BMP4 heterozygous null mice and modifications by Gli3 and Alx4. Dev Biol188:235-247.
35.
Eastell R., Reid DM, Compston J., Cooper C., Fogelman I., Francis RM, et al. (1998). A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med244:271-292.
36.
Ernst M., Rodan GA (1991). Estradiol regulation of insulin-like growth factor-I expression in osteoblastic cells: evidence for transcriptional control. Mol Endocrinol5:1081-1089.
37.
Ernst M., Heath JK, Rodan GA (1989). Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology125:825-833.
38.
Favier B., Rijli FM, Fromental-Ramain C., Fraulob V., Chambon P., Dolle P. (1996). Functional cooperation between the non-paralogous genes Hoxa-10 and Hoxd-11 in the developing forelimb and axial skeleton. Development122:449-460.
39.
Fraser JK, Lill MC, Figlin RA (1996). The biology of the cytokine sequence cascade. Sem Oncol23(Suppl 4):2-8.
40.
Fromental-Ramain C., Warot X., Lakkaraju S., Favier B., Haack H., Birling C., et al. (1996). Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeletal patterning. Development122:461-472.
41.
Galien R., Evans HF, Garcia T. (1996). Involvement of CCAAT/enhancer-binding protein and nuclear factor-KB binding sites in interleukin-6 promoter inhibition by estrogens. Mol Endocrinol10:713-722.
42.
Geoffrey V., Ducy P., Karsenty G. (1995). A PEBP2 /AML1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element. J Biol Chem270:30973-30979.
43.
Gottlicher M., Heck S., Herrlich PA (1998). Transcriptional cross-talk, the second mode of steroid hormone receptor action. ) Mol Med76:480-489.
44.
Graves DT (1999). The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis28:482-490.
45.
Hamamori Y., Wu HY, Sartorelli V., Kedes L. (1997). The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist. Mol Cell Biol17:6563-6573
46.
Hofbauer LC, Khosla S., Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL (1999). Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology140:4367-4370.
47.
Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N., Ortiz de Luna RI, et al. (1997). Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet15:36-41.
48.
Howell TH, Fiorellini JP, Paquette DW, Offenbacher S., Giannobile WV, Lynch SE (1997). A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol68:1186-1193.
labs EW, Muller U., Li X., Ma L., Luo W., Haworth IS, et al. (1993). A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell75:443-450.
51.
Jee WS, Ma YF (1997). The in vivo anabolic actions of prostaglandins in bone. Bone21:297-304.
52.
Ji C., Casinghino S., McCarthy TL, Centrella M. (1996). Cloning, characterization and expression of the transforming growth factor-β type I receptor promoter in fetal rat bone cells. J Cell Biochem63:478-492.
53.
Ji C., Casinghino S., McCarthy TL, Centrella M. (1997). Multiple and essential Spl binding sites in the promoter for transforming growth factor-β type I receptor. I Biol Chem272:21260-21267.
54.
Ji C., Casinghino S., Javed A., Ito Y., Hiebert SW, Lian JB, et al. (1998). CBF (AML/PEBP2)-related elements in the TGF-β type I receptor promoter and expression with osteoblast differentiation. J Cell Biochem69:353-363.
55.
Kalu DN, Arjmandi BH, Liu C.-C., Salih MA, Birnbaum RS (1994). Effects of ovariectomy and estrogen on the serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bone Miner25:135-148.
56.
Kassem M., Okazaki R., De Leon D., Harris SA, Robinson JA, Spelsberg TC, et al. (1996). Potential mechanism of estrogen-mediated decrease in bone formation: estrogen increases production of inhibitory insulin-like growth factor-binding protein-4. Proc Assoc Am Physicians108:155-164.
57.
Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell89:755-764.
58.
Kose KN, Xie JF, Carnes DL, Graves DT (1996). Pro-inflammatory cytokines downregulate platelet derived growth factor-alpha receptor gene expression in human osteoblastic cells. J Cell Physiol166:188-197.
59.
Kream BE, Tetradis S., Lafrancis D., Fall PM, Feyen JH, Raisz LG (1997). Modulation of the effects of glucocorticoids on collagen synthesis in fetal rat calvariae by insulin-like growth factor binding protein-2. I Bone Miner Res12:889-895.
60.
Lane NE, Lukert B. ( 1998). The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am27:465-483.
61.
Lekstrom-Himes J., Xanthopoulos KG (1998). Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem273:28545-28548.
62.
Levanon D., Negreanu V., Berstein Y., Bar-Am I., Avivi L., Groner Y. (1994). AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics23:425-432.
63.
Levi G., Topilko P., Schneider-Maunory S., Lasagna M., Mantero S., Cancedda R., et al. (1996). Defective bone formation in Krox-20 mutant mice. Development122:113-120.
64.
Li M., Jee WS, Ke HZ, Liang XG, Lin BY, Ma YF, et al. (1993). Prostaglandin E2 restores cancellous bone to immobilized limb and adds bone to overloaded limb in right hindlimb immobilization rats. Bone14:283-288.
65.
Lind M. ( 1998). Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand283(Suppl):2-37.
66.
Lorenzo JA, Sousa SL, Centrella M. (1988). Interleukin-1 in combination with transforming growth factor-alpha produces enhanced bone resorption in vitro. Endocrinology123:2194-2200.
67.
Manolagas SC (1995). Role of cytokines in bone resorption. Bone2(Suppl):63S-67S.
68.
Marusic A., Kalinowski JF, Harrison JR, Centrella M., Raisz LG, Lorenzo JA (1991). Effects of transforming growth factor β and interleukin 1α on prostaglandin synthesis in serum-deprived osteoblastic cells. J Immunol146:2633-2638.
69.
Martin JF, Bradley A., Olson EN (1995). The paired-like homeobox gene MHox is required for early events of skeletogenesis in multiple lineages. Genes Dev9:1237-1249.
70.
Massague I. (1998). TGF-beta signal transduction. Ann Rev Biochem67:753-791.
71.
McCarthy TL, M. Centrella (1993). Regulation of IGF activity in bone. In: Advances in experimental medicine and biology: current directions in insulin-like growth factor research. LeRoith D, Raizada MK, editors. New York: Plenum Publishing Corporation, pp. 407-414.
72.
McCarthy TL, Centrella M., Canalis E. (1989a). Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology124:1247-1253.
73.
McCarthy TL, Centrella M., Canalis E. (1989b). Effects of fibroblast growth factors on deoxyribonucleic acid and collagen synthesis in rat parietal bone cells. Endocrinology125:2118-2126.
74.
McCarthy TL, Centrella M., Canalis E. (1990a). Cortisol inhibits the synthesis of insulin-like growth factor I in bone cell cultures. Endocrinology126:1569-1575.
75.
McCarthy TL, Centrella M., Canalis E. (1990b). Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. J Biol Chem265:15353-15356.
76.
McCarthy TL, Centrella M., Raisz LG, Canalis E. (1991). Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. Endocrinology128:2895-2900.
77.
McCarthy TL, Thomas MI, Centrella M., Rotwein P. (1995). Regulation of insulin-like growth factor I transcription by cyclic AMP in fetal rat bone cells through an element within exon 1: protein kinase A dependent control without a consensus cyclic AMP response element. Endocrinology136:3901-3908.
78.
McCarthy TL, Ji C-H., Shu H., Casinghino S., Crothers K., Rotwein P., et al. (1997). 17β-estradiol potently suppresses cAMP induced insulin-like growth factor-I (IGF-1) gene activation in primary rat osteoblast cultures. J Biol Chem272:18132-18139.
79.
McCarthy TL, Ji C., Chen Y., Kim K., Centrella M. (2000). Time- and dose-related interactions between glucocorticoid and cAMP on C/EBP-dependent IGF-I expression by osteoblasts. Endocrinology (in press).
Merriman HL, van Wijnen AJ, Hiebert S., Bidwell JP, Fey E., Lian J., et al. (1995). The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/runt domain transcription factor family: interactions with the osteocalcin gene promoter. Biochemistry34:13125-13132.
82.
Meyers S., Lenny N., Hiebert SW (1995). The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol15:1974-1982.
83.
Mierke DF, Pellegrini M. (1999). Parathyroid hormone and parathyroid hormone-related protein: model systems for the development of an osteoporosis therapy. Curr Pharm Des5:21-36.
84.
Miyoshi H., Ohira M., Shimizu K., Mitani K., Hirai H., Imai T., et al. (1995). Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res23:2762-2769.
85.
Mo R., Freer AM, Zinyk DL, Crackower MA, Michaud J., Heng HH, et al. (1997). Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and development. Development124:113-123.
86.
Mundlos S., Otto F., Mundlos C., Mulliken JB, Aylsworth AS, Albright S., et al. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell89:773-779.
87.
Niehof M., Manns MP, Trautwein C. (1997). CREB controls LAP/C/EBP β transcription. Mol Cell Biol17:3600-3613.
88.
Oelgeschlager M., Nuchprayoon I., Luscher B., Friedman AD (1996). C/EBP, c-Myb, and PU. 1 cooperate to regulate the neutrophil elastase promoter. Mol Cell Biol16:4717-4725.
89.
Ogawa E., Inuzuka M., Maruyama M., Satake M., Naito-Fujimoto M., Ito Y., et al. (1993a). Molecular cloning and characterization of PEBP2beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2. Virology194:314-331.
90.
Ogawa E., Maruyama M., Kagoshima H., Inuzuka M., Lu J., Satake M., et al. (1993b). PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci USA90:6859-6863.
91.
Otto F., Thornell AP, Crompton T., Denzel A., Gilmour KC, Rosewell IR, et al. (1997). Cbfa 1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell89:765-771. 1.
92.
Poli V. ( 1998). The role of C/EBP isoforms in the control of inflammatory and native immunity function. J Biol Chem273:29279-29282.
93.
Raisz LG (1988). Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med318:818-828.
94.
Raisz LG (1995). Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr125(Suppl):2024S-2027S.
95.
Rifas L. (1999). Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcif Tissue Int64:1-7.
96.
Rodan GA, Martin TJ (1981). Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int33:349-351.
97.
Salih MA, Liu CC, Arjmandi BH, Kalu DN ( 1993). Estrogen modulates the mRNA levels for cancellous bone protein of ovariectomized rats. Bone Miner23:285-299.
98.
Sato F. Ouchi Y., Masuyama A., Nakamura T., Hosoi T., Okamoto Y., et al. (1993). Effects of estrogen replacement on insulin-like growth factor I concentrations in serum and bone tissue and on interleukin I secretion from spleen macrophages in oophorectomized rats. Cafcif Tissue Int53:111-116.
99.
Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A., et al. (1994). Tamoxifen and estrogen lower circulating lipoprotein (a) concentrations in healthy postmenopausal women. Arterioscler Thromb14:1586-1593.
100.
Spelsberg TC, Subramaniam M., Riggs BL, Khosla S. (1999). The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol13:819-828.
101.
Stein B., Yang MX ( 1995). Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-KB and C/EBPβ. Mol Cell Biol15:4971-4979.
102.
Suda T., Takahashi N., Udagawa N. limi E., Gillespie MT, Martin TJ (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev20:345-357.
103.
Szebenyi G., Fallon JF (1999). Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol185:45-106.
104.
Thirunavukkarasu K., Mahajan M., McLarren KW, Stifani S., Karsenty G. (1998). Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa 1 contribute to its transactivation function and its inability to heterodimerize with Cbf. Mol Cell Biol18:4197-4208.
105.
Thomas MJ, Umayahara Y., Shu H., Centrella M., Rotwein P., McCarthy TL (1996). Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E2 in osteoblasts. I Biol Chem271:21828-218354.
106.
Toung JS, Griffin A., Ogle RC, Lindsey WH (1998). Repair of nasal defects using collagen gels containing insulin-like growth factor 1. Laryngoscope108:1654-1658.
107.
Turner RT (1999). Mice, estrogen, and postmenopausal osteoporosis. J Bone Miner Res14:187-191.
108.
Turner RT, Bachup P., Kline BC, Colvard DS, Spelsberg TC (1991). Evidence that the inhibition of osteoblast activity by estrogen is preceded by down regulation of IGF-I gene expression and that these changes are estrogen receptor mediated. In: Molecular concepts of insulin-like growth factors. Spencer EM, editor. New York: Elsevier, pp. 143-153.
109.
Turner RT, Bachup P., Sherman PJ, Hill E., Evans GL, Spelsberg TC (1992). Mechanism of action of estrogen on intramembranous bone formation: regulation of osteoblast differentiation and activity. Endocrinology131:883-889
110.
Turner RT, Evans GL, Wakley GK (1993). Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: inhibition of indices of formation and resorption. J Bone Miner Res8:359-366.
111.
Umayahara Y., Ji C., Centrella M., Rotwein P., McCarthy TL (1997). CCAAT/enhancer binding protein delta (C/EBPδ) activates insulin-like growth factor-1 gene transcription in osteoblasts: identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem272:31793-31800.
112.
Umayahara Y., Billiard I., Ji C., Centrella M., McCarthy TL, Rotwein P. (1999). CCAAT/enhancer binding protein 8 is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. J Biol Chem274:10609-10617.
113.
Wedel A., Ziegler-Heitbrock HWL (1995). The C/EBP family of transcription factors. Immunobiology193:171-185.
114.
Williams SC, Cantwell CA, Johnson PF (1991). A family of C/EBP related proteins capable of forming covalently linked leucine zipper dimers in vitro. Genes Dev5:1553-1567.
115.
Wilson ME (1998). Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor 1. J Clin Endocrinol Metab83:2018-2028.
116.
Wozney JM, Rosen V. (1998). Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Rel Res346:26-37. Wrana JL (1998). TGF-beta receptors and signalling mechanisms. Miner Electrolyte Metab24:120-130.
117.
Yamada T., Tobita K., Osada S., Nishihara T., Imagawa M. (1997). CCAAT/enhancer-binding protein 8 gene expression is mediated by APRF/STAT3. J Biochem121:731-738.
118.
Yamada T., Tsuchiya T., Osada S., Nishihara T., Imagawa M. (1998). CCAAT/enhancer-binding protein 8 gene expression is mediated by autoregulation through downstream binding sites. Biochem Biophys Res Commun242:88-92.
119.
Yamamoto K., Arakawa T., Ueda N., Yamamoto S. (1995). Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-EI cells. J Biol Chem270:31315-31320.
120.
Zellin G. (1998). Growth factors and bone regeneration: implications of barrier membranes. Swed Dent I129(Suppl):7-65.
121.
Zhang D-R., Hetherington CJ, Meyers S., Rhoades KL, Larson CJ, Chen H-M., et al. (1996). CCAAT enhancer binding protein (C/EBP) and AML-1 (CBFalpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol16:1231-1240.
